Financials

v3.5.0.2
Consolidated Balance Sheets - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current Assets    
Cash $ 473,921 $ 232,984
Trade accounts receivable, net 474,924 154,436
Inventory, net 130,530 61,051
Total Current Assets 1,079,375 448,471
Current Liabilities    
Accounts payable and accrued expenses 408,194 167,481
Notes payable, net of discount 214,115 100,000
Total Current Liabilities 622,309 267,481
Immudyne, Inc. Stockholders' equity    
Common stock, $0.01 par value; 50,000,000 shares authorized, 34,697,875 and 32,010,375 shares issued, 34,678,512 and 32,010,375 outstanding as of September 30, 2016 and December 31, 2015, respectively 346,978 320,103
Additional paid-in capital 9,032,728 8,366,313
Accumulated (deficit) (9,075,014) (8,586,338)
Equity 304,692 100,078
Treasury stock,19,363 shares, at cost (4,720)
Total Immudyne, Inc. Stockholders' Equity 299,972 100,078
Non-controlling interest 157,094 80,912
Total Stockholders' Equity 457,066 180,990
Total Liabilities and Stockholders' Equity $ 1,079,375 $ 448,471

Source

v3.5.0.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Net sales $ 1,384,429 $ 279,883 $ 4,252,704 $ 845,513
Cost of sales 942,738 73,988 2,981,657 237,707
Gross Profit 441,691 205,895 1,271,047 607,806
Operating expenses        
Compensation and related expenses 361,829 101,137 1,077,340 301,301
Professional fees 82,608 29,237 277,282 91,059
General and administrative expenses 204,958 57,580 382,857 206,841
Total operating expenses 649,395 187,954 1,737,479 599,201
Operating Income (Loss) (207,704) 17,941 (466,432) 8,605
Interest (expense) (9,992) (14,422) (15,805) (33,048)
Net Income (Loss) Before Taxes (217,696) 3,519 (482,237) (24,443)
Deferred income tax benefit 4,600 13,200
Net Income (Loss) (217,696) 8,119 (482,237) (11,243)
Net income (loss) attributable to noncontrolling interests 8,955 6,439
Net income (loss) attributable to Immudyne, Inc. $ (226,651) $ 8,119 $ (488,676) $ (11,243)
Basic and diluted (loss) per share attributable to Immudyne, Inc. $ (0.01) $ 0.00 $ (0.02) $ (0.00)
Average number of common shares outstanding        
Basic 34,427,087 30,650,000 31,917,873 30,663,306
Diluted $ 34,427,087 $ 30,650,000 $ 31,917,873 $ 30,663,306

Source

v3.5.0.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (Loss) $ (482,237) $ (11,243)
Adjustments to reconcile net (loss) to net cash (used) by operating activities    
Depreciation 43,748
Bad debt provision (43,558)
Amortization of debt discount 5,990
Deferred tax benefit (13,200)
Stock compensation expense 493,218 14,500
Issuance of warrants for services 20,585
Changes in Assets And Liabilities    
Trade accounts receivable (276,930) (116,754)
Inventory (69,479) 1,579
Accounts payable and accrued expenses 240,713 1,059
Net cash (used) by operating activities (111,698) (80,311)
CASH FLOWS FROM FINANCING ACTIVITIES    
Investment in subsidiary by noncontrolling interest 161,355
Increase in notes payable 150,000 205,000
Repayment of notes payable (115,522)
Sale of common stock and warrants 46,000
Purchase of treasury stock (4,720) (10,800)
Net cash provided by financing activities 352,635 78,678
Net increase (decrease) in cash 240,937 (1,633)
Cash at beginning of the period 232,984 75,495
Cash at end of the period 473,921 73,862
Supplemental Disclosure of Cash Flow Information    
Cash paid during the period for interest 8,563 24,547
Issuance of common stock for notes payable 10,200
Issuance of common stock in relation to debt offering 41,875
Issuance of common stock for services $ 581,093

Source